A Previously Undescribed Intron and Extensive 5' Upstream Sequence, but Not Phox2a-mediated Transactivation, Are Necessary for High Level Cell Type-specific Expression of the Human Norepinephrine Transporter Gene*

Chun-Hyung Kim, Hee-Sun Kim, Joseph F. CubellsDagger , and Kwang-Soo Kim§

From the Department of Neurology and Department of Anatomy and Neurobiology, University of Tennessee College of Medicine, Memphis, Tennessee 38163 and Dagger  Department of Psychiatry, Veterans Affairs Connecticut Health Care System and Yale University School of Medicine, West Haven, Connecticut 06516

    ABSTRACT
Top
Abstract
Introduction
References

The synaptic action of norepinephrine is terminated by NaCl-dependent uptake into presynaptic noradrenergic nerve endings, mediated by the norepinephrine transporter (NET). NET is expressed only in neuronal tissues that synthesize and secrete norepinephrine and in most cases is co-expressed with the norepinephrine-synthetic enzyme dopamine beta -hydroxylase (DBH). To understand the molecular mechanisms regulating human NET (hNET) gene expression, we isolated and characterized an hNET genomic clone encompassing approximately 9.5 kilobase pairs of the 5' upstream promoter region. Here we demonstrate that the hNET gene contains an as-yet-unidentified intron of 476 base pairs within the 5'-untranslated region. Furthermore, both primer extension and 5'-rapid amplification of cDNA ends analyses identified multiple transcription start sites from mRNAs expressed only in NET-expressing cell lines. The start sites clustered in two subdomains, each preceded by a TATA-like sequence motif. As expected for mature mRNAs, transcripts from most of these sites each contained an additional G residue at the 5' position. Together, the data strongly support the authenticity of these sites as the transcriptional start sites of hNET. We assembled hNET-chloramphenicol acetyltransferase reporter constructs containing different lengths of hNET 5' sequence in the presence or the absence of the first intron. Transient transfection assays indicated that the combination of the 5' upstream sequence and the first intron supported the highest level of noradrenergic cell-specific transcription. Forced expression of the paired-like homeodomain transcription factor Phox2a did not affect hNET promoter activity in NET-negative cell lines, in marked contrast to its effect on a DBH-chloramphenicol acetyltransferase reporter construct. Together with our previous studies suggesting a critical role of Phox2a for noradrenergic-specific expression of the DBH gene, these data support a model in which distinct, or partially distinct, molecular mechanisms regulate cell-specific expression of the NET and DBH genes.

    INTRODUCTION
Top
Abstract
Introduction
References

The synaptic action of norepinephrine (NE)1 is terminated primarily by rapid, NaCl-dependent re-uptake into presynaptic nerve terminals. NE reuptake is mediated by the norepinephrine transporter (NET) located in the plasma membrane of noradrenergic neurons (1). The NET is a major target for tricyclic antidepressant drugs and for illicit drugs such as cocaine and amphetamine. These agents block NE transport by the NET, resulting in enhancement of the synaptic activity of NE. Blockade of NET is an important mechanism of therapeutic action of tricyclic antidepressants, and this observation provided support for the catecholamine hypothesis of depression (2). Recently, Klimek et al. (3) reported that the level of NET is significantly reduced in the locus coeruleus from major depressive subjects. These observations suggest that regulation of NET expression could play an important role in human mental illnesses such as major depression and schizophrenia (3, 4). In rodent studies, the mouse NET (mNET) locus, Slc6a5, overlapped with a quantitative trait locus (Lore4) for differential ethanol sensitivity in long-sleep and short-sleep mice (5-7). Together with previous studies indicating ethanol-induced changes of noradrenergic neurotransmission (8, 9), these findings suggest the additional possibility that regulation of NET expression may contribute to ethanol tolerance and/or addiction.

A cDNA encoding human NET (hNET) was isolated by an expression cloning approach (10), and subsequently, cDNAs for the bovine and the rat NET genes were cloned on the basis of their sequence homologies (11, 12). NET belongs to a superfamily of Na+- and Cl--dependent transporters that includes transporters for dopamine, serotonin, gamma -aminobutyric acid, betaine, glycine, proline, and taurine (13-16). Recently, genomic clones of the hNET and mouse placental NET (mNET) have been isolated and characterized. The hNET gene, spanning approximately 45 kb, consists of 14 exons separated by 13 introns and is located on chromosome 16q12.2 (17). The structure of the mNET gene was found to be similar to that of the hNET gene. The mNET gene is composed of 14 exons spanning approximately 36 kb and is located on chromosome 8 which is homologous with 16q12.2 of the human genome (5).

In the brain, NET is specifically expressed in noradrenergic neurons but is not expressed either in dopaminergic neurons (e.g. substantia nigra) or in adrenergic neurons (e.g. C1 and C2 cell groups), demonstrating that NET is a hallmark protein of noradrenergic cells (18). Another protein selectively expressed in noradrenergic (and adrenergic) neurons is dopamine beta -hydroxylase (DBH) which catalyzes the conversion of dopamine to noradrenaline (19, 20). Collectively, NET and DBH are tightly co-expressed in noradrenergic neurons but differentially in adrenergic neurons, such as those in the C1 and C2 cell groups (18). These findings suggest that NET gene expression is subject to stringent cell type-specific control mechanisms that overlap with, but are not identical to, those regulating DBH gene expression.

Levels of NET mRNA in noradrenergic neurons and neurosecretory cells are acutely or chronically regulated in response to various physiological and pharmacological signals including reserpine (21), glucocorticoids (22), leukemia inhibitory factor, and ciliary neurotrophic factor (23), angiotensin II (24), retinoic acid (23), nerve growth factor (22), and protein kinase C (25). The foregoing observations suggest that changes in NET gene expression induced by physiological or pharmacological stimuli may alter noradrenergic transmission depending on physiological demand.

Despite the clinical and physiological significance of NET gene regulation, little is known about the transcriptional control mechanisms governing its expression. To investigate transcriptional regulation of the human NET gene, we isolated and analyzed genomic clones that encompass the 5'-flanking promoter region of the human NET gene. Here we report that the human NET gene contains an as-yet-unidentified intron of 476 bp in the middle of the 5'-untranslated region. Multiple transcription start sites of the hNET gene were detected by both primer extension analysis and the 5'-RACE technique. On the basis of this information, we constructed several hNET-chloramphenicol acetyltransferase reporter constructs. Transient transfection assays of these reporter constructs in both NET-positive and NET-negative cell lines show that combination of the 5' upstream sequences and the first intron is critical for high level noradrenergic cell type-specific promoter activity of the hNET gene. However, the paired-like homeodomain transcription factor Phox2a, which is critical for noradrenergic cell type-specific DBH promoter activity (26, 27), appears not to regulate the promoter activity of the hNET gene.

    EXPERIMENTAL PROCEDURES

Isolation and Characterization of hNET Genomic Clones-- A 0.5-kb rat NET cDNA fragment corresponding to the base pairs 990-1512 of the coding sequence (21) was radiolabeled by the random primer method and used as the probe to screen a lambda EMBL3 human genomic library derived from placenta chromosomal DNA (CLONTECH, Mountain View, CA). Positive clones were isolated and characterized by restriction mapping, using the same rat NET cDNA probe. Then these clones were retested by genomic Southern blot analyses. An oligonucleotide HN3-1 with the nucleotide sequence, 5'-GCATGGATGCGGCTGGCGAGAGGAA-3', which encompasses the start codon of hNET cDNA (see Ref. 10; Fig. 6), was radiolabeled by T4 polynucleotide kinase using [gamma -32P]dATP and was used as the probe. This probe discriminates the genomic clones containing the 3' side of the gene, thereby facilitating identification of candidate clones that contain the transcription start site and the 5' upstream region of the hNET gene. The final positive clones (clones 3 and 7), which hybridized with both cDNA and oligonucleotide probes, were isolated and further analyzed by restriction enzyme mapping and sequence determination. Nucleotide sequences were analyzed using the MacDNASIS 3.0 program (Hitachi Software).

Cell Culture and mRNA Isolation-- Human neuroblastoma SK-N-BE(2)C and SK-N-BE(2)M17, rat pheochromocytoma PC12, mouse central noradrenergic neuron-derived CATH.a, and peripheral nervous system-derived PATH.2 cell lines were maintained as described previously (28-30). Human cholinergic neuroblastoma SK-N-MC (31), HeLa, thyroid carcinoma, rat C6 glioma, and mouse mastocytoma cell lines were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (HyClone), 100 µg/ml streptomycin, and 100 units/ml penicillin in a CO2 incubator. Poly(A)+ RNA was prepared from each cell line by oligo(dT)-cellulose affinity column chromatography as described (32) and used for determination of the transcription start site and Northern blot analysis.

Primer Extension-- Primer extension analysis was performed based on the procedure previously described (32) with some modification. Briefly, an oligonucleotide primer 8A, 5'-GTGTCCGGCGGCGAGGGGATCCCTGGTGCCTTGCGCCCT-3', complementary to hNET nucleotides +142 to +180 (Fig. 6), was 5'-end-labeled with [gamma -32P]dATP and T4 polynucleotide kinase. Approximately 1 × 105 cpm of 32P-labeled oligonucleotide was mixed with 5 µg of poly(A)+ RNA isolated from SK-N-BE(2)M17, SK-N-BE(2)C, and HeLa cells in a 30-µl reaction containing 10 mM Tris-HCl, pH 8.3, 150 mM KCl, and 1 mM EDTA. Five µg of yeast tRNA served as a negative control. The oligonucleotide was annealed to RNA by heating the mixture at 100 °C for 5 min followed by incubation at 42 °C for 16 h. The annealed primer was extended by incubating with SUPERSCRIPT II RNase H- Reverse Transcriptase (Life Technologies, Inc.) in a 20-µl reaction containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 40 units of RNasin, and 1 mM dNTPs (1 mM 7-deaza-dGTP, 1 mM dCTP, 1 mM dATP, and 1 mM dTTP) at 42 °C for 1 h. The reaction products were analyzed on a 6% denaturing polyacrylamide gel. The sizes of the extension products were determined by counting the number of nucleotides in a concurrently run sequencing ladder using a control template (the bacteriophage M13mp18) and a control primer with the nucleotide sequence, 5'-GTTTTCCCAGTCACGAC-3'. In an additional experiment, another oligonucleotide primer 7A, 5'-TCCGCCGTGTGG CGTTCGGGCGGGGCCGGGGAAGAGCT-3', complementary to nucleotides from +47 to +84 bp of the hNET gene (Fig. 6) was used as the primer.

5'-Rapid Amplification of cDNA Ends (5'-RACE)-- To identify the 5'-end of the hNET mRNA, 5'-RACE was carried out as described (33) with the following modifications (Fig. 4A). Poly(A)+ RNA from SK-N-BE(2)M17 cells was reverse-transcribed with SUPERSCRIPT II RNase H- Reverse Transcriptase by priming with the oligonucleotide HN3-1. Because the 5'-flanking region of hNET gene is highly GC-rich, 7-deaza-dGTP was used along with the other 3 dNTPs for synthesizing cDNA. A 3' poly(A) tail was added to the cDNA by terminal deoxynucleotidyltransferase (Life Technologies, Inc.). The product was subjected to the first PCR using an adaptor-(dT)17 primer HN5A, 5'-GGAGACTCGAGTCGACATCGA(T)17 -3', and HN3-1. 40 cycles of PCR were performed with the temperature profile of 95 °C for 40 s, 55 °C for 40 s, and 72 °C for 1 min, which was followed by additional incubation at 72 °C for 9 min. An aliquot of the product was subsequently used for the PCR using an adaptor primer HN5, 5'-GGAGACTCGAGTCGACATCG-3', and an hNET gene-specific inner primer HN3-2, 5'-TGGCGAGAGGAACTTTACCGG-3' (Fig. 6). The second PCR was run for 25 cycles of the same temperature profile as that of the first PCR. To improve the specificity of DNA amplification, MasterampTM PCR Optimization Kit (Epicentre Technologies) was used according to the manufacturer's protocol for both the first and second rounds of PCR. The final PCR products were directly cloned into pCRII (Invitrogen). Insert DNAs were isolated from individual colonies and sequenced (34).

Northern Blot Analysis-- Two micrograms of poly(A)+ RNA prepared from each cell line were fractionated on a formaldehyde agarose gel, transferred to a nylon membrane, and hybridized with radiolabeled probes. To detect DBH messages, cDNA probes for the rat (35) and human (29) DBH genes were labeled and used as a mixture. To detect NET messages, the rat NET cDNA fragment (21) was radiolabeled and used as a probe. In addition, a cDNA fragment of 700 bp, encompassing the mouse NET cDNA from middle of exon 1 to exon 6 (a kind gift from Dr. Randy Blakely, Vanderbilt University), was also used as a probe. A cDNA fragment for the mouse glyceraldehyde-3-phosphate dehydrogenase was used as a positive control. These probes were labeled with [alpha -32P]dATP using Klenow fragment and random hexamer priming. Blots were autoradiographed on an intensifying screen for 6 to 24 h at -70 °C according to the relative strength of signals. For rehybridization, previous signals were removed by thoroughly washing the membrane at 80 °C in 1.5 mM NaCl, 0.15 mM sodium citrate, pH 7, 0.01% SDS until no signal was detected after overnight exposure.

Reporter Gene Constructs and Transient Transfection Assay-- pBLCAT3-1 is a derivative of pBLCAT3 (36) which was constructed by deleting the CRE-like sequence and TATA-like sequence upstream of the multiple cloning site (26). Several NET-CAT reporter constructs were prepared using pBLCAT3-1 as follows. A 14-kb SalI fragment of hNET clone 3 (Fig. 1) was cloned into pBLCAT3-1 that was cut with SalI. The resulting plasmid was digested with BamHI, ligated, and named as pNET9000CAT. For the construct containing promoter plus the first intron, intronic sequence was amplified by PCR using sense primer (5'-ACCAGGGATCCCCTCGCCGCCGGACAC-3') and antisense primer (5'-TCGCGGATCCGAATTCTGGCGAGAGGAACTTTACCGG-3'), digested with BamHI, and subcloned into pNET9000CAT that had been digested with BamHI to yield pNET9000(i)CAT. Based on previous observations that less than 1.5-kb upstream sequence of the hDBH gene drives cell-specific expression (29, 37, 38), we also made pNET-CAT constructs that contain an hNET upstream sequence of comparable length. For this purpose, approximately 1.4-kb upstream region of the hNET gene was amplified by PCR using pNET9000CAT as the template with a sense primer of 5'-GTGCCAAGCTTGATTCGGATAGCGATGTAA-3' and an antisense primer of 5'-CGAGGGGATCCCTGGTGCC-3'. The PCR product was digested with HindIII and BamHI and subcloned into the pBLCAT3-1 that had been cut with the same enzymes, resulting in pNET1400CAT. The first intron was similarly subcloned into pNET1400CAT, generating pNET1400(i)CAT. The orientation of the first intron in pNET9000(i)CAT and pNET1400(i)CAT was confirmed by sequence analysis.

Transfection was performed by the calcium phosphate coprecipitation procedure as described previously (28, 29). Plasmids for transfection were prepared using Qiagen columns (Qiagen Co., Santa Clarita, CA). For the SK-N-BE(2)C and SK-N-BE(2)M17 cell lines, each 60-mm dish was transfected with an equimolar amount (0.5 pmol) of each reporter construct, 1 µg of pRSV-beta gal, varying amounts of the effector plasmid, and pUC19 plasmid to a total of 5 µg of DNA. For the other cell lines, twice as much DNA was used in transfection. To compare the NET promoter activity in NET-positive and NET-negative cell lines, the CAT activity driven by reporter constructs are compared with that driven by pRSV-CAT plasmid which contains the Rous sarcoma virus (RSV) enhancer/promoter. Due to its strong promoter activity, a one-tenth molar amount of the reporter construct (0.05 or 0.1 pmol) was used for pRSV-CAT plasmid in transient transfection assay. In cotransfection analysis, a half molar amount of the reporter construct was used for the Phox2a-expressing plasmid, pRc/Phox2a, which was described previously (26, 27). Cells were harvested 72 h after transfection, lysed by freeze-thaw cycles, and assayed for CAT activities. To correct for differences in transfection efficiencies among different DNA precipitates, CAT activity was normalized to that of beta -galactosidase. CAT and beta -galactosidase activities were assayed as described previously (28, 29).

    RESULTS

Isolation and Sequencing of hNET Genomic Clones That Contain the 5'-Flanking Sequences-- Eight positive clones, containing insert DNAs of 6-14 kb length, were isolated by screening approximately 1.5 × 106 plaque-forming units of a lambda EMBL3 human genomic library with a 0.5-kb cDNA probe corresponding to the N-terminal 167 amino acids of the rat NET gene. On subsequent Southern blot analysis, clones 3 and 7 hybridized to an oligonucleotide probe encompassing the translational start codon of hNET. Clones 3 and 7 contained insert DNAs of 14 and 12 kb, respectively, of overlapping sequence (Fig. 1A). Further restriction mapping and Southern blot analyses indicated that the BamHI-SacI fragment residing at the 3' side of both clones contained the start codon of hNET (Fig. 1, A and B). Clones 3 and 7 contained approximately 9.5- and 7.5-kb sequence upstream of the start codon of hNET, respectively.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   Southern blot analysis and organization of the hNET genomic clones. A, the structure of the hNET genomic clones #3 and #7. Black boxes denote the first three exons as described by Porzgen et al. (17). The relative position of the translation start codon is indicated by the arrow. Clones 3 and 7 contained substantially overlapping insert DNAs of 14 and 12 kb. Locations of restriction enzyme sites are shown as follows: S, SalI; E, EcoRI; B, BamHI; C, SacI. B, Southern blot analysis of restriction fragment. The genomic DNA was cut with SalI (lane 1), SalI and EcoRI (lane 2), SalI and BamHI (lane 3), or SacI (lane 4) and was probed with a radiolabeled oligonucleotide HN3-1 that encompasses the start codon. Positions of size markers are indicated on the left. C, comparison of nucleotide sequences of the cDNA and genomic clones of hNET gene immediately 5' to the start codon. The nucleotide sequence of the corresponding region of the mouse NET genomic clone (5) is also shown. The translation start codon (ATG) is boxed. The nucleotide sequences of the cDNA and genomic clones of hNET diverge after a perfect match of 51 bases. In contrast, the sequence homology continues beyond this junction between the genomic sequences of human and mouse NET genomic clones. At the junction of divergence, a consensus splicing acceptor sequence, 5'-AG-3', is found and denoted by a circle.

Sequence analyses of the BamHI-SacI fragment of both clones 3 and 7 demonstrated that it includes the start codon, untranslated leader sequence, and an exon described as the first exon in previous reports (10, 17), and a part of an intron (Fig. 1A) previously described as the first intron (17). Surprisingly, however, the nucleotide sequences of the genomic clone diverged from the published untranslated leader sequence starting at the base 52 bp upstream of the start codon, following perfect matches of 51 bases (Fig. 1C). Both clones 3 and 7 contained the same nucleotide sequences in this area, indicating that these are not cloning artifacts. In addition, the corresponding nucleotide sequence of the mouse genomic NET clone shows significant homology with that of hNET clone (Fig. 1C; see Ref. 5). The presence of a consensus splice acceptor site (5'-AG-3') in the genomic sequence at the junction of divergence suggested the possibility that the human NET gene contains an as-yet-unidentified intron(s) in the middle of the leader sequence. To investigate these findings in detail, the insert DNA of clone 3 was subjected to structural and functional analyses as follows.

An Intron of 476 bp Resides in the 5'-Untranslated Leader Sequence of hNET-- To assess whether the hNET gene contained an additional intron(s) in the leader sequence, we determined additional nucleotide sequences upstream of the start codon and compared this sequence to the remaining 9 bases of the previously described leader sequence of hNET (see Ref. 10; Fig. 1C). As shown in Fig. 2 (also see Fig. 6), the sequence of clone 3, corresponding to 528-536 bp upstream of the start codon, perfectly matched the remaining leader sequence, 5'-GCCGGACAC-3' (Fig. 1C). This observation strongly suggests that the intervening 476-bp region represents an as-yet-unidentified intron of the hNET gene. Also consistent with this hypothesis, the putative intervening sequence contains a consensus splicing donor site (5'-GT-3') at its 5' end in addition to an acceptor site (5'-AG-3') at the 3' end (Fig. 2). Furthermore, eight out of nine nucleotides at the potential exon/intron junction area match the consensus sequence (5'-(A/C)AG/GT(A/G)AGT-3'; see Ref. 39) and as would be expected, a pyrimidine-rich sequence precedes the acceptor site (Fig. 6). Based on these observations, we conclude that the first intron of 476 bp length resides in the middle of the untranslated leader sequence of hNET. Primer extension and 5'-RACE analyses further substantiated this conclusion and identified the full untranslated leader sequences of hNET, as follows.


View larger version (6K):
[in this window]
[in a new window]
 
Fig. 2.   Comparison of the sequences of the hNET genomic clone and hNET cDNA. The remaining 9 bases of the 5' side of the leader sequence of hNET is observed in the upstream region of the genomic sequence after the intervening region of 476 bases, suggesting that this region represents an as-yet-unidentified intron. In support of this, the conserved GT/AG splice donor/acceptor motifs were found at these junctions and are denoted by boxes.

Mapping of the Transcription Start Sites of hNET mRNA-- To identify the transcription start site(s) of hNET mRNA, primer extension analysis was performed using poly(A)+ RNAs prepared from SK-N-BE(2)M17, SK-N-BE(2)C, and HeLa cell lines. When the mRNAs from SK-N-BE(2)M17 and SK-N-BE(2)C were primed with the primer 8A, extended cDNA products appeared at multiple locations, clustered in two areas. The first of these clusters occurred between 176 and 184 bp and the second between 208 and 212 bp, upstream of the 3' utmost base of the primer 8A, respectively (Fig. 3). In a separate experiment using the distinct primer 7A, two clusters of multiple bands were similarly detected at corresponding locations (data not shown). In contrast, no such clusters of extension products were detected when mRNA from HeLa cells was used as the template, suggesting that these bands represent catecholamine cell-specific cDNA products of NET mRNA. Several bands detected in both NET-positive and -negative samples (denoted by asterisks in Fig. 3) appear to be nonspecific products, probably generated due to the GC-rich structure of the proximal hNET promoter (Fig. 6). None of these bands, specific or nonspecific, were detected when yeast tRNA was used as the template. Together, the data suggest that the two catecholamine cell-specific clusters of bands, located approximately 180 and 210 bp upstream of the primer 8A, represent multiple transcription start sites for hNET mRNAs.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 3.   Determination of the hNET gene transcription start sites by primer extension analysis. Primer extension was performed with the 39-nucleotide antisense primer 8A using poly(A)+ RNA from the human neuroblastoma SK-N-BE(2)C (lane 3) and SK-N-BE(2)M17 (lane 4) as NET-positive system, and from human HeLa (lane 2) as NET-negative system. In addition, the same amount of yeast tRNA was used in parallel as the negative control (lane 1). The sequencing reaction on the left side of the autoradiogram was carried out using M13 primer (-40) on an M13mp18 single-stranded DNA template and used to size the extension products. Two brackets at the right side of the panel, together with indicated sizes, indicate two clusters of several start sites. Nonspecific products generated with both NET-positive and -negative mRNAs are indicated by asterisks.

To establish whether the multiple bands identified in the above primer extension analyses represent genuine transcription start sites of hNET, we next performed nested 5'-RACE experiments using poly(A)+ RNAs prepared from SK-N-BE(2)M17 cells by priming with the antisense oligonucleotide HN3-1, the sequence of which corresponds to the translation start codon and its immediate upstream 21 nucleotides (Figs. 4A and 6). Following reverse transcription and poly(A) tailing, PCR was performed using the adaptor primer HN5A and the antisense primer HN3-1. This first PCR generated two major products of approximately 310- and 280-bp lengths (data not shown), which were used as the template in the second PCR with another adaptor primer HN5 and an inner hNET primer HN3-2 which partially overlaps with HN3-1 (Figs. 4A and 6). Two major products of approximately 300- and 270-bp lengths were prominently detected by gel analysis (Fig. 4B). Assuming that the potential intron of 476-bp length is spliced out, the sizes of the PCR products match well with the putative two clustered transcription start sites identified in the above primer extension analyses.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Determination of the hNET gene transcription start sites by 5'-RACE. A, a diagram showing the procedure of 5'-RACE analysis of hNET mRNA. 1, single-stranded cDNA was synthesized from SK-N-BE(2)M17 mRNA by priming with the oligonucleotide HN3-1 and subsequently digested with RNase H. 2, the cDNA was then tailed with poly(A) at its 3' side and used as template in two consecutive nested PCR using adaptor primers and hNET-specific inner primers as indicated (steps 3 and 4). B, ethidium bromide staining of 5'-RACE products. Two RACE products (300 and 270 bp in size) were generated as denoted by two arrows. A 1-kb DNA ladder (Life Technologies, Inc.) was run in parallel as a size marker. C, sequence analysis of 22 independent subclones of the smaller product (~270 bp) identified 5 different transcription start sites and all contained additional G residue, indicating that they represent mature hNET RNA molecules. Nucleotide sequences around the transcription start site of the 5'-RACE products are shown at the right side of each sequence panel. Next to these sequences are also shown the nucleotide sequences of the corresponding genomic sequences of the hNET gene. The additional G residue is indicated by an asterisk. D, in contrast, all 10 subclones of the larger product (~300 bp) included the same sequence and did not contain an additional G residue.

We isolated and subcloned the second PCR products of 5'-RACE into pCRII vector. Sequence analysis of 32 individual clones showed that all these clones contained the previously identified leader sequence of hNET, indicating that they were derived from the intact hNET cDNAs (see below). The putative first intron which represents the genomic sequences at 527 to 52 bp upstream of the start codon were missing in all RACE products, demonstrating that this sequence indeed represent the first intron of the hNET gene. Along with the above gel analysis of PCR products (Fig. 4B), our sequencing analysis of 5'-RACE products indicates that there is no alternate splicing of this newly identified first intron in hNET mRNAs of the SK-N-BE(2)M17 cell line. Among 22 individual isolates that were cloned from the smaller molecular weight (~270 bp) products, 5 transcription start sites were found to be clustered at 233 to 227 bp upstream of the start codon in hNET mRNAs (Fig. 6; it is to be noted that transcription start sites are shown to be at 709 to 703 bp upstream of the start codon since it includes the intronic sequence); 1 clone contained an apparent initiation site at the A located 233 bp upstream of the ATG codon, 10 clones at the G 231 bp upstream, 6 clones at the G 230 bp upstream, 2 clones at the C 228 bp upstream, and 3 clones at the A 227 bp upstream. Remarkably, all these 22 clones were found to contain an additional G residue expected for intact mRNA capped at the 5' end (Fig. 4C and data not shown; see Ref. 40). These results strongly suggest that the foregoing nucleotides represent authentic start sites of mature hNET transcripts. We next isolated 10 individual clones from the larger product (~300 bp) and compared their nucleotide sequences. All 10 clones included the same nucleotide sequences with the 5' termini residing at the C residue 259 bp upstream of the start codon, suggesting that this site is another major transcription start site of the hNET gene (Fig. 4D). However, in contrast to the smaller RACE products, these clones did not contain the additional G residue. Therefore, the authenticity of this C residue as the transcription start site remains open to question. Given that all 10 clones isolated from the larger product exhibited the same sequence without the additional G residue and that the size matches well with the primer extension result, we favor the possibility that the larger form(s) of hNET mRNA are generated without capping at the 5' site. Taken together, we conclude that hNET transcription starts at multiple sites clustered at two areas approximately 30 bases apart from each other. The extra G residues at the 5' positions of most RACE products further supports the authenticity of these transcription start sites. Among these, we arbitrarily designated the G residue 231 bp upstream of the translation start site as +1 because both primer extension analysis and RACE indicated this site is the most common apparent initiation site that contains a capping G residue.

NET Is Co-expressed with DBH in Several Catecholaminergic Cell Lines-- As a first step toward investigating transcriptional regulation of the hNET gene, we tested several cell lines for expression of NET mRNA. Northern blot analysis of poly(A)+ RNA, from five catecholamine-synthesizing (human neuroblastoma SK-N-BE(2)C and SK-N-BE(2)M17, rat pheochromocytoma PC12, and mouse CATH.a and PATH.2) and five noncatecholamine-synthesizing (human HeLa, human cholinergic neuroblastoma SK-N-MC11, rat glioma C6, human thyroid carcinoma, and mouse mastocytoma) cell lines, showed that SK-N-BE(2)C and SK-N-BE(2)M17 cells express two NET mRNAs (3.6 and 5.8 kb in length), whereas PC12 cells preferentially express the larger 5.8-kb transcript (Fig. 5A). All three of those cell lines also robustly express tyrosine hydroxylase (TH) and DBH messages (Fig. 5B; 27). NET mRNA was not detectable in mouse CATH.a and PATH.2 whether hNET (Fig. 5A) or mouse NET cDNA (data not shown) was used as the probe, despite clear expression of TH and DBH transcripts (Fig. 5B; 27). Thus, most, but not all, catecholamine-synthesizing cell lines express NET at levels detectable by Northern blot analysis. None of the five non-catecholaminergic cell lines expressed NET or DBH mRNA, despite abundant expression of glyceraldehyde-3-phosphate dehydrogenase mRNA, used as a control for mRNA recovery (Fig. 5C).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 5.   Cell-specific expression of NET mRNAs in catecholaminergic cell lines. Poly(A)+ RNAs were isolated from five catecholaminergic cell lines including human neuroblastoma SK-N-BE(2)C, SK-N-BE(2)M17, rat pheochromocytoma PC12, mouse CATH.a, and mouse PATH.2 cell lines and five noncatecholaminergic cell lines including human HeLa, SK-N-MC, thyroid carcinoma, rat C6, and mouse mastocytoma cell lines and were analyzed by Northern blot as described under "Experimental Procedures." The membrane was consecutively hybridized for mRNAs encoding NET (A) and DBH (B) and then hybridized with glyceraldehyde-3-phosphate dehydrogenase probe (C). The location of each mRNA was determined by comparison with RNA size standards (Life Technologies, Inc.).

Sequence Analysis of the 5'-Flanking Promoter Region of the hNET Gene-- We determined the nucleotide sequence up to 4.8-kb upstream of the start codon (GenBankTM accession number AF061198). Nucleotide sequences including the first intron and the 5' proximal 554-bp region are presented in Fig. 6. We numbered the position of each nucleotide based on the major transcription start site which is arbitrarily designated as +1 site (denoted by the bent arrow in Fig. 6). Two areas encompassing two clustered transcription start sites centered at -28 and +1, respectively, and individual nucleotides identified as transcription start sites in primer extension and 5'-RACE analyses are indicated by asterisks above each base. A TATA-like sequence (TTAAT) is found at -64/-60, which may control transcription initiation at around -28 bp. Intriguingly, a second TATA-like sequence (TACATTA) is found at -30/-24bp, that presumably controls transcription initiation at around +1. This suggests the interesting possibility that the second TATA sequence area may work both as the TATA box and as a transcription initiation site. These analyses show that mature hNET mRNAs, once the first 476-bp intron is spliced out, contain untranslated leader sequences of 227-259 bp (Fig. 6). Like other neurotransmitter transporter genes (41-44), the proximal promoter region of hNET is highly GC-rich. The leader sequence contains 77% GC residues and the first 200-bp upstream region contains 72% GC residues.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 6.   Nucleotide sequences of the 5'-flanking region of the hNET gene. The first 18 amino acids of hNET are shown under the nucleotide sequences in a single-letter code. The nucleotide sequences of the newly identified first intron are indicated by lowercase letters. Numbers at the right and left side are the nucleotide positions relative to one of the major transcription initiation sites designated as +1 and is indicated by a bent arrow. All nucleotide bases identified as transcriptional start sites are denoted by asterisks. Two TATA-like sequences, residing approximately 30 bp upstream of the transcription start sites, are indicated by boxes and designated as TATA1 and TATA2. Potential transcription factor binding sites such as Sp1-binding site (GC box), E-box, C/EBP-binding site, CRE-like sequence, and CCAAT box are indicated by boxes. The nucleotide sequences of oligonucleotides used as primers in the primer extension and 5'-RACE analyses are underlined. The GenBankTM accession number for this proximal and additional upstream sequences is AF061198.

The location and nucleotide sequence of potential cis-regulatory elements are summarized in Table I, and those residing in the proximal promoter area are shown in Fig. 6. The potential cis-regulatory elements residing in the upstream sequence include four AP1-binding sites, seven CCAAT boxes, two C/EBP motifs, a cAMP response element (CRE)-like motif, a Oct1-binding site, seven Sp1-binding sites, and a sterol response element. Notably, the first intron area also contains multiple cis-regulatory elements such as sterol response element, C/EBP, E-box, CRE, and Sp1-binding sites. Our sequence search, however, did not identify sequence motif(s) with significant homology to restrictive element/neuron-restrictive silencer element that appears to regulate a large number of neuronal genes (45-47).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Potential transcription factor recognition sites in the hNET gene
The location of each potential cis-element is indicated relative to the transcription start site. (c) at the right side of the location shows that the cis-element is found in the complementary sequence. We included two consensus Sp1 sites here because both motifs are shown to be authentic Sp1-binding sites.

Cell-specific Promoter Activity of the hNET Gene Requires Both the 5' Upstream Sequences and the First Intron-- Based on the structural organization of the hNET genomic clone, we wished to identify the promoter/enhancer region(s) containing critical regulatory function for cell-specific transcriptional activity. For this purpose, we assembled four reporter gene constructs, containing hNET 5' sequences, with or without the putative first intron. NET9000CAT and NET1400CAT plasmids contained 9.0- and 1.4-kb nucleotide sequences upstream of the transcription start site, respectively, fused to the reporter gene, chloramphenicol acetyltransferase (CAT). NET9000(i)CAT and NET1400(i)CAT plasmids, in addition to those upstream sequences, included the newly identified first intron as well (Fig. 7A). The transcriptional activities of these constructs were examined by transient transfection assay in four different cell lines. As shown in Fig. 7B, NET9000CAT-driven reporter gene expression was approximately 4-7-fold higher in NET-expressing cell lines compared with that in NET-negative cell lines. In NET/DBH-positive cell lines, the relative CAT activity driven by this construct was approximately 50% that driven by the DBH-CAT construct (DBH978CAT) containing the 978-bp upstream sequence of the human DBH gene (29, 38). In negative cell lines, the CAT activities driven by NET9000CAT and DBH978CAT are comparable. These results strongly suggest that the upstream 9.0-kb sequence contains important regulatory information for the cell-specific expression of the hNET gene. CAT activity driven by NET1400CAT was approximately 20% that by NET9000CAT in NET-positive cell lines, indicating that the upstream region between -9.0 and -1.4 kb may contain positive regulatory sequence element(s) required for the full promoter activity of the hNET gene. In contrast the CAT activity driven by NET1400CAT is not significantly higher (less than 2-fold) in NET-positive cell lines compared with that in NET-negative cell lines, suggesting that the proximal 1.4-kb flanking region may have some, but not sufficient, information for driving cell-specific NET gene expression (Fig. 7, B and C). This is in sharp contrast to the case of hDBH gene regulation, in which a relatively short upstream sequence (<1.1 kb) contains sufficient information for the cell-specific expression both in transgenic mice and transient transfection experiments (26, 29, 37, 38). Taken together, it appears that the upstream region at -9.0 to -1.4 kb imparts substantial cell-type specificity to hNET expression, and the proximal 1.4-kb sequence may have general promoter function (Fig. 7C).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Promoter activities of the 5'-flanking and upstream regions of the hNET gene. A, diagrams showing the structures of hNET-CAT reporter constructs. The bent arrow represents the major transcription start site of hNET, designated as +1 in this study. The bold line denotes the 5'-untranslated leader sequence, and the thin line denotes the 5' upstream sequence of the hNET gene. The shaded box represents the first intron of hNET, identified in this study, which resides in the leader sequence. B, promoter activities of hNET-CAT constructs in NET-positive SK-N-BE(2)C (BE) and SK-N-BE(2)M17 (M17) and NET-negative C6 and HeLa cell lines. Levels of CAT reporter gene activity were determined by transient transfection assays and expressed relative to that of pRSV-CAT plasmid which shows universally high promoter activity in all cell lines used. Due to its strong promoter activity, only one-tenth the relative amount of the pRSV-CAT construct was used in the transient transfection assays (see "Experimental Procedures"). The normalized CAT activity driven by pRSV-CAT in each cell line was set to 100 to compare the relative strength of each reporter construct. The numbers shown in the table are the average of triplicate samples, with variation less than 20%. This experiment has been repeated twice more in triplicate using independently prepared plasmid DNAs, resulting in similar patterns. Each sample was assayed in different dilutions so that the final cpm were in the linear range. C, schematic diagrams showing the location of potential regulatory elements in the 5' upstream region and the first intron of the human NET gene. The relative transcription-promoting/enhancing activities in NET-positive (NET+) and NET-negative (NET-) cell lines are indicated as very strong (+++), strong (++), moderate (+), and weak (+/-). As indicated in this diagram, the 1.4-kb proximal sequence was not sufficient for driving cell-specific NET gene expression. Instead, the upstream region at -9.0 to -1.4 kb of the hNET gene appears to have cell type-specific promoter activity, whereas the first intron exhibits a strong transcription-enhancing activity.

The First Intron of the hNET Gene Exerts Important Transcription Enhancing Activity-- Inclusion of the first intron in NET9000CAT reporter constructs increased transcriptional activity 30-40-fold in NET-positive cell lines (Fig. 7B). It also increased the CAT activity by approximately 3-15-fold in NET-negative cell lines. When the first intron was included in the shorter NET1400CAT construct, it increased the transcriptional activity by approximately 15- and 10-fold, respectively, in NET-positive and NET-negative cell lines. Our results suggest that the first intron of the hNET gene exerts a moderate general enhancer effect on transcription and a stronger cell-specific enhancing effect in noradrenergic cell lines in the context of the long upstream sequence. Collectively, our transient transfection assay indicates that the fullest cell-specific transcriptional activity of the hNET gene so far examined requires both the 5' upstream region up to 9.0 kb and the first intron residing in the untranslated leader sequence.

The combination of the 9.0-kb upstream sequence and the first intron drove a remarkably high level of noradrenergic cell-specific expression of the reporter gene, comparable to 30-40% that driven by the intact RSV promoter/enhancer (Fig. 7B). At present, it is not clear why NET9000(i)CAT drove much higher CAT expression than that by DBH978CAT in SK-N-BE(2)C and SK-N-BE(2)M17 cell lines, given that the steady state mRNA levels of DBH and NET are comparable in these cells (Fig. 5).

Phox2a Does Not Influence NET Transcriptional Activity, a Marked Contrast to DBH-- Based on the critical role of the paired-like homeodomain transcription factor Phox2a for noradrenergic-specific promoter activity of the DBH gene (26, 27, 48), and the co-expression pattern of DBH and NET in most noradrenergic neurons (18), we hypothesized that Phox2a may co-regulate DBH and NET transcription. To test this hypothesis, we examined the effect of forced expression of Phox2a on NET promoter function. In agreement with previous studies (26, 27), cotransfection of Phox2a significantly increased (approximately 10-fold) the transcriptional activity of DBH978CAT in DBH/NET-negative HeLa and C6 cell lines (Fig. 8; data not shown). In contrast, forced expression of Phox2a in these cell lines did not affect hNET promoter activity, in either NET-expressing or non-expressing cells, regardless of the presence or absence of the first intron in the reporter construct (Fig. 8; data not shown). These data suggest that in contrast to the DBH gene, the Phox2a does not exert a strong influence on cell-specific expression of the NET gene.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 8.   Differential transactivation of the hDBH and hNET promoters by the paired-like homeodomain transcription factor Phox2a. The DBH-CAT or NET-CAT reporter construct was cotransfected with Phox2a-expressing plasmid (pRc/Phox2a), in a molar ratio of 0.5, in each cell line indicated. pRc/CMV plasmid is used as an empty control. The CAT activity driven by each reporter construct by itself was set to 1.0 to compare transactivation by Phox2a. Fold induction by Phox2a cotransfection is presented as mean ± S.E. values from six samples.


    DISCUSSION

To understand molecular mechanisms regulating transcription of the hNET gene, we isolated a genomic clone containing approximately 9.5 kb of the 5' upstream region of the hNET gene. The experiments presented here have defined critical aspects of the promoter structure and function of hNET gene, including the following: (i) the location of transcription start site(s); (ii) the sequence of the full 5'-untranslated leader sequence; (iii) the sequence of approximately 5 kb of the 5'-flanking promoter region, including a search for potential cis-regulatory motifs; (iv) most unexpected, an as-yet-unidentified region of the hNET gene that appears by multiple criteria to be the first intron and which resides in the middle of the 5'-untranslated leader sequence; and (v) that the combination of the upstream 9-kb sequence and the first intron is critical for the high level, noradrenergic-specific transcriptional activity of the hNET gene. Finally, we tested, and rejected, the hypothesis that Phox-2a transactivation regulates hNET expression, as it does DBH expression.

Promoter Structure of the hNET Gene-- Data from previous studies have shown that the coding region of the human NET gene consists of 14 exons disrupted by 13 introns (10, 17), with the entire 5'-untranslated leader sequence present in the first exon, and the intron immediately 3' to that first exon designated intron 1 (17). In contrast to these earlier findings, the studies described here demonstrate that the hNET gene contains an additional 476-bp-long intron in the middle of the 5'-untranslated leader sequence. Several pieces of evidence support this conclusion as follows: (i) the nucleotide sequences of two independent genomic clones (clones 3 and 7) diverge from that of the 5' leader sequence previously identified (10), following a perfect match of 51 bases immediately upstream of the start codon; (ii) the remaining 9 bases of the leader sequence appear at the 5' end of the putative intron of 476 bp; (iii) the intervening sequence contains the consensus splicing donor and acceptor sites at both junctions; and (iv) this 476-bp sequence is missing in all RACE products isolated and cloned in the present studies. We therefore conclude that the hNET gene contains an additional exon at the 5' utmost area and that the first intron of 476 bp resides in the middle of the 5'-untranslated leader sequence. In addition, Porzgen et al. (49) recently reported that the hNET mRNA is alternatively spliced at its 3' region, in agreement with the Northern blot experiment showing more than one transcript (Fig. 5), and thus contains an additional exon at its 3' side of the gene.

The region both upstream and downstream from the transcriptional start sites is rich in GC sequence, having an average GC content of 77 and 72% in the leader sequence and the first 200-bp upstream region, respectively. Previous studies likewise reported that the proximal upstream regions of other transporter gene family contain high GC content (41-44). It seems likely that secondary structure in these GC-rich regions might explain why previous analyses did not identify the putative first intron described here (17). In support of this possibility, successful determination of the transcription start sites by 5'-RACE and primer extension analyses described in this study was possible only after extensive optimization of these procedures, including substitution of 7-deaza-dGTP in the synthesis of cDNA:RNA template from poly(A)+ RNA in the primer extension and 5'-RACE experiments. In addition, specific PCR-enhancing agents included in the MasterampTM PCR Optimization Kit (Epicentre Technologies) were necessary to amplify specific products of the correct size. Furthermore, we found that both the sequence and the length of the primer were crucial for generating the specific products in primer extension analysis (data not shown). Data from our primer extension analysis and 5'-RACE experiments strongly suggest that transcription of the hNET gene initiates at multiple sites clustered at two locations, one at 703-711 bp and the other at 735-739 bp upstream of the start codon in the genomic sequence. Given that the first intron is missing in all cDNA isolates from 5'-RACE, this indicates that the 5' leader sequences of hNET mRNAs are of approximately 230- and 260-bp lengths. In support of this, PCR analysis of the 5'-RACE generated two major products of corresponding lengths (Fig. 3). Two TATA-like sequence motifs reside approximately 30 bp upstream of each location, respectively, suggesting that the hNET gene contains two alternate promoters. The locations of transcription start sites are further confirmed by sequence analyses of individual clones of 5'-RACE and PCR products, which all mapped to the above two locations. Most of these clones (22 out of 32 isolates) contained an extra G residue at their 5' ends, which was not present in the hNET genomic sequence (Fig. 3). Given that most mature eukaryotic mRNAs are capped at the 5' end (40), these findings strongly support these locations as authentic transcription start sites of hNET mRNAs. Among these multiple sites, we designated the G residue which is 707 bp upstream of the start codon as +1 (Fig. 6). It is worth noting that the 5' leader sequences do not contain any ATG codons, indicating that the ATG codon previously identified by Pacholczyk et al. (10) is the genuine start codon of hNET.

Largely Overlapping but Also Distinct Expression Pattern of NET and DBH-- DBH and NET are both hallmark proteins of noradrenergic cell types because they are responsible for biosynthesis and reuptake of noradrenaline, respectively, in the nervous system. In contrast to NET, DBH is also expressed in cells that synthesize and release epinephrine. An exhaustive in situ hybridization study showed that the majority (>90%) of noradrenaline-containing cell bodies in the brainstem express NET mRNA, whereas it is not detected at all in dopaminergic or adrenergic cell bodies (18). Outside the nervous system, some non-neuronal tissues, such as the placental syncytiotrophoblast (50), also express NET mRNA. Most, but not all, norepinephrine-synthesizing cells in the adult nervous system co-express DBH and NET. The vast majority of cells that express NET, with only rare exceptions, also express DBH. Understanding similarities and differences in the molecular mechanisms governing cell type-specific expression of DBH and NET promises to shed light on how different classes of neurons express overlapping but distinct biochemical phenotypes.

Various cell lines derived from catecholaminergic cell types are available and have been used in different laboratories to study catecholamine gene regulation and neuronal differentiation. Among these, PC12, from the rat pheochromocytoma (51), is the prototype cell line and has been extensively used in different laboratories. Several human neuroblastoma cell lines, e.g. SK-N-BE(2)C and SK-N-BE(2)M17, are of neural crest origin and express catecholamine-synthesizing enzyme genes (29, 52). CATH.a and PATH.2 cells derived from brain and adrenal tumors, respectively, in transgenic mice carrying the SV40 T antigen gene driven by a portion of the TH promoter were also shown to express catecholamine-synthesizing enzyme genes (30). To assess whether NET is co-expressed in these catecholaminergic cell lines along with catecholamine synthetic enzyme genes, Northern blot analysis was performed using NET and DBH cDNAs as the probe. As expected, all five noncatecholaminergic cell lines tested in this study showed no detectable levels of TH, DBH, or NET, suggesting that expression of these genes is strongly suppressed in these cell lines. Also as expected, all five catecholaminergic cell lines abundantly expressed DBH (Fig. 3) and TH message (27). In contrast, and to our surprise, NET message, although easily detected in PC12, SK-N-BE(2)C, and SK-N-BE(2)M17, was not detected in CATH.a and PATH.2 cells. Thus, most, but not all, of the catecholaminergic cell lines examined expressed NET. The CATH.a cell line, derived from a central noradrenergic neuronal population, did not express any detectable level of NET. It is possible that the CATH.a cell line has lost its capability to express NET while it continues to express synthesizing enzymes, TH and DBH, or that NET mRNA expression occurs at a low level in this cell line, below the limits of detection of Northern blot analysis. Alternatively, based on the in vivo observation that small portions (approximately 10% or less) of noradrenergic cells of the brainstem express DBH but not NET (18), the CATH.a cell line may have originated from these DBH+/NET- cell populations. Likewise, PATH.2 cells did not express detectable levels of NET mRNA.

Cell Type-specific Expression of NET, Potential Role of the 5' Upstream Sequence and the First Intron-- To define promoter regions important for driving cell-specific transcriptional activity of the hNET gene, transient transfection assays using multiple cell line systems were performed. The results are summarized schematically in Fig. 7. 5' sequence up to 9.0 kb appears to contribute to cell-specific promoter activity of the hNET gene. In addition, the newly described first intron contains information that appears necessary for full high level expression of the reporter gene in all cell lines examined. Interestingly, the 1.4-kb upstream sequence of the hNET gene was not sufficient at all for the high level, noradrenergic-specific expression of the reporter gene. This is in contrast to that of the hDBH gene, in which a relatively short upstream sequence (<1.1 kb) is necessary and sufficient for cell-specific expression of the reporter gene both in transgenic mouse experiments (37, 53-56) and in transient transfection assays using cultured cell lines (26, 29, 38). Similarly, a relatively short upstream sequence of the rat DBH gene was shown to drive the cell-specific expression of the reporter gene (57). In addition, there is no evidence available to suggest a role of the intronic sequence for cell-specific transcription of the DBH gene. In this regard, it is worth noting that reporter gene expression driven by NET9000(i)CAT was much higher than that driven by DBH978CAT or other longer DBH-CAT constructs (Fig. 7B; data not shown), despite the fact that steady state mRNA levels of DBH and NET were comparable in the cell lines used in this assay (Fig. 5). Thus, one interesting possibility to explain this discrepancy is that full expression of the DBH gene may also require as yet undiscovered sequence information residing in areas other than the 5' upstream region, e.g. intron(s). Alternatively, the enhancer activity of the first intron of the hNET gene may be modest in the intact chromatin and may have been exaggerated in our transient transfection assay. Finally, it is possible that NET mRNA is less stable than DBH mRNA and therefore requires higher levels of transcription for maintenance of similar steady state levels. Further work is necessary to address these issues. In other eukaryotic genes, ever increasing evidence suggests that the intronic sequences play a crucial role in cell type-specific regulation of a variety of genes (58, 59). Given the high degree of structural similarity among the NaCl-dependent transporter genes, and their generally extremely specific patterns of expression, it will be of great interest to see whether cell type-specific expression of transporter genes other than NET also requires intronic sequence information.

Cell Type-specific Expression of NET: How Similar to or Distinct from DBH Is It?-- In the nervous system, noradrenergic neurons constitute a tiny proportion (<0.0001%) of the total brain neurons. Therefore, it is striking that the majority (>90%) of noradrenaline-containing cell bodies co-express DBH and NET. Based on these observations, we and others (18) have postulated that NET gene expression may be closely linked to control mechanisms that specify other hallmark phenotypes of noradrenergic neurons, such as DBH expression. Recent studies showed the paired-like homeodomain transcription factor Phox2a is restrictively expressed in noradrenergic and adrenergic cell types (60, 61) and regulates development of major noradrenergic populations including the locus coeruleus (48). Furthermore, Phox2a apparently contributes to the phenotypic specification of noradrenergic cells by directly transactivating the DBH promoter activity (26, 27). The above observations prompted us to examine whether Phox2a co-regulates the promoter activities of the hNET and hDBH genes (Fig. 8). Intriguingly, forced expression of Phox2a in NET/DBH/Phox2a-negative cell lines did not change the promoter activity of the hNET gene at all, although it significantly up-regulated that of the hDBH gene. Based on these data, we hypothesize that Phox2a may not regulate the cell-specific expression of the NET gene and that at least partially distinct control mechanisms underlie cell-specific expression of NET and DBH. In this context, it is worthwhile to note that these genes are subject to different modes of regulation in response to some pharmacological and physiological stimuli. For instance, reserpine treatment in rat decreases the NET mRNA both in the adrenal gland and the locus coeruleus (21) whereas it increases TH and DBH expression (62-64). Although the mechanism of induction of TH by reserpine is trans-synaptic, the down-regulation of NET expression is not (65). Likewise, dexamethasone treatment appeared to regulate DBH and NET mRNA expression in opposite directions (22, 66). Collectively, these observations suggest the modes and mechanisms controlling NET and DBH gene expression in response to cell-specific as well as various physiological signals may differ in important ways. Further work to define the similarities and differences in these mechanisms will contribute to a better understanding of the regulation of specification of catecholamine cell phenotypes.

In summary, our study defined the structural organization of the 5'-flanking promoter of the hNET gene. (i) We identified a new intron of 476 bp that resides in the middle of the 5'-untranslated leader sequence; (ii) we determined multiple transcription start sites, clustered at two loci, by primer extension and 5'-RACE analyses; and (iii) we determined the nucleotide sequence of the approximate 5-kb upstream sequence. We have shown that the combination of the upstream sequence and the first intron is required for driving the cell type-specific transcriptional activity of the hNET gene. Furthermore, despite their striking co-expression in most noradrenergic neurons, our results suggest that differential control mechanisms may underlie the cell type-specific expression of the DBH and NET genes. The present study will serve as a basis for future studies of NET gene regulation and for studies of coordinate regulation of catecholamine-specific neuronal phenotypes.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant MH48866 (to K. S. K.) and by the Department of Veterans Affairs Grant DA 00167 (to J. F. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF061198.

§ To whom correspondence should be addressed. Present address: Molecular Neurobiology Laboratory, McLean Hospital, Harvard Medical School, 115 Mill St., Belmont, MA 02178. Tel.: 617-855-2024; Fax: 617-855-3479; E-mail: kskim{at}mclean.harvard.edu.

    ABBREVIATIONS

The abbreviations used are: NE, norepinephrine; NET, norepinephrine transporter; DBH, dopamine beta -hydroxylase; CAT, chloramphenicol acetyltransferase; 5'-RACE, 5'-rapid amplification of cDNA ends; h, human; m, mouse; PCR, polymerase chain reaction; kb, kilobase pair; bp, base pair; RSV, Rous sarcoma virus; TH, tyrosine hydroxylase.

    REFERENCES
Top
Abstract
Introduction
References
  1. Axelrod, J., and Kopin, I. J. (1969) Prog. Brain Res. 31, 21-32[Medline] [Order article via Infotrieve]
  2. Schildkraut, J. J. (1965) Am. J. Psychiatry 122, 509-522[Medline] [Order article via Infotrieve]
  3. Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H. Y., Kalka, S., Dilley, G., and Ordway, G. A. (1997) J. Neurosci. 17, 8451-8458[Abstract/Free Full Text]
  4. Giros, B., and Caron, M. G. (1993) Trends Pharmacol. Sci. 14, 43-49[CrossRef][Medline] [Order article via Infotrieve]
  5. Fritz, J. D., Jayanthi, L. D., Thoreson, M. A., and Blakely, R. D. (1998) J. Neurochem. 70, 2241-2251[Medline] [Order article via Infotrieve]
  6. Markel, P. D., Bennett, B., Beeson, M., Gordon, L., Simpson, V. J., and Johnson, T. E. (1996) Mamm. Genome 7, 408-412[CrossRef][Medline] [Order article via Infotrieve]
  7. Markel, P. D., Bennett, B., Beeson, M., Gordon, L., and Johnson, T. E. (1997) Genome Res. 7, 92-99[Abstract]
  8. Israel, Y., Carmichael, F. J., and Macdonald, J. A. (1973) Ann. N. Y. Acad. Sci. 215, 38-48[Medline] [Order article via Infotrieve]
  9. Lin, A. M. Y., Bickford, P. C., Palmer, M. R., and Gerhardt, G. A. (1993) Neurosci. Lett. 164, 71-75[CrossRef][Medline] [Order article via Infotrieve]
  10. Pacholczyk, T., Blakely, R. D., and Amara, S. G. (1991) Nature 350, 350-354[CrossRef][Medline] [Order article via Infotrieve]
  11. Lingen, B., Bruss, M., and Bonisch, H. (1994) FEBS Lett. 342, 235-238[CrossRef][Medline] [Order article via Infotrieve]
  12. Bruss, M., Porzgen, P., Bryan-Lluka, L. J., and Bonisch, H. (1997) Mol. Brain Res. 52, 257-262[CrossRef][Medline] [Order article via Infotrieve]
  13. Amara, S. G., Sonders, M. S., Zahniser, N. R., Povlock, S. L., and Daniels, G. M. (1998) Adv. Pharmacol. 42, 164-168[Medline] [Order article via Infotrieve]
  14. Amara, S. G., and Kuhar, M. J. (1993) Annu. Rev. Neurosci. 16, 73-93[CrossRef][Medline] [Order article via Infotrieve]
  15. Barker, E. L., and Blakely, R. D. (1995) in Psychopharmacology: The Fourth Generation of Progress (Bloom, F. E., and Kupfer, D. J., eds), pp. 321-333, Raven Press, Ltd., New York
  16. Uhl, G. R. (1992) Trends Neurosci. 15, 265-268[CrossRef][Medline] [Order article via Infotrieve]
  17. Porzgen, P., Bonisch, H., and Bruss, M. (1995) Biochem. Biophys. Res. Commun. 215, 1145-1150[CrossRef][Medline] [Order article via Infotrieve]
  18. Lorang, D., Amara, S. G., and Simerly, R. B. (1994) J. Neurosci. 14, 4903-4914[Abstract]
  19. Kirshner, N., and Goodall, M. (1957) J. Biol. Chem. 226, 207-212[Free Full Text]
  20. Friedman, S., and Kaufman, S. (1965) J. Biol. Chem. 240, 4763-4773[Free Full Text]
  21. Cubells, J. F., Kim, K. S., Baker, H., Volpe, B. T., Chung, Y., Houpt, T. A., Wessel, T. C., and Joh, T. H. (1995) J. Neurochem. 65, 502-509[Medline] [Order article via Infotrieve]
  22. Wakade, A. R., Wakade, T. D., Poosch, M., and Bannon, M. J. (1996) J. Physiol. (Lond.) 494, 67-75[Abstract]
  23. Matsuoka, I., Kumagai, M., and Kurihara, K. (1997) Brain. Res. 776, 181-188[CrossRef][Medline] [Order article via Infotrieve]
  24. Lu, D., Yu, K., Paddy, M. R., Rowland, N. E., and Raizada, M. K. (1996) Endocrinology 137, 763-772[Abstract]
  25. Bonisch, H., Hammermann, R., and Bruss, M. (1998) Adv. Pharmacol. 42, 183-186[Medline] [Order article via Infotrieve]
  26. Kim, H. S., Seo, H., Brunet, J. F., and Kim, K. S. (1998) J. Neurosci. 18, 8247-8260[Abstract/Free Full Text]
  27. Yang, C., Kim, H. S., Seo, H., Kim, C. H., Brunet, J. F., and Kim, K. S. (1998) J. Neurochem. 71, 1813-1826[Medline] [Order article via Infotrieve]
  28. Kim, K. S., Ishiguro, H., Tinti, C., Wagner, J., and Joh, T. H. (1994) J. Neurosci. 14, 7200-7207[Abstract]
  29. Ishiguro, H., Kim, K. T., Joh, T. H., and Kim, K. S. (1993) J. Biol. Chem. 268, 17987-17994[Abstract/Free Full Text]
  30. Suri, C., Fung, B. P., Tischler, A. S., and Chikaraishi, D. M. (1993) J. Neurosci. 13, 1280-1291[Abstract]
  31. Ross, R. A., Biedler, J. L., Spengler, B. A., and Reis, D. J. (1981) Cell. Mol. Neurobiol. 1, 301-311[Medline] [Order article via Infotrieve]
  32. Kim, K. S., Febraio, M., Han, T. H., Wessel, T. C., Park, D. H., and Joh, T. H. (1995) in A Practical Approach: Gene Probes 2 (Rickwood, D., and And Hames, B. D., eds), pp. 151-182, Oxford University Press, Oxford
  33. Frohman, M. A., Dush, M. K., and Martin, G. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8998-9002[Abstract]
  34. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467[Abstract]
  35. Kim, K. S., Tinti, C., Song, B., Cubells, J. F., and Joh, T. H. (1994) J. Neurochem. 63, 834-842[Medline] [Order article via Infotrieve]
  36. Luckow, B., and Schutz, G. (1987) Nucleic Acids Res. 15, 5490[Medline] [Order article via Infotrieve]
  37. Hoyle, G. W., Mercer, E. H., Palmiter, R. D., and Brinster, R. L. (1994) J. Neurosci. 14, 2455-2463[Abstract]
  38. Seo, H., Yang, C., Kim, H. S., and Kim, K. S. (1996) J. Neurosci. 16, 4102-4112[Free Full Text]
  39. Breathnach, R., and Chambon, P. (1981) Annu. Rev. Biochem. 50, 349-383[CrossRef][Medline] [Order article via Infotrieve]
  40. Hirzmann, J., Luo, D., Hahnen, J., and Hobom, G. (1993) Nucleic Acids Res. 21, 3597-3598[Medline] [Order article via Infotrieve]
  41. Bengel, D., Heils, A., Petri, S., Seemann, M., Glatz, K., Andrews, A., Murphy, D. L., and Lesch, K. P. (1997) Mol. Brain. Res. 44, 286-292
  42. Bradley, C. C., and Blakely, R. D. (1997) J. Neurochem. 69, 1356-1367[Medline] [Order article via Infotrieve]
  43. Donovan, D. M., Vandenbergh, D. J., Perry, M. P., Bird, G. S., Ingersoll, R., Nanthakumar, E., and Uhl, G. R. (1995) Mol. Brain Res. 30, 327-335[CrossRef][Medline] [Order article via Infotrieve]
  44. Kawarai, T., Kawakami, H., Yamamura, Y., and Nakamura, S. (1997) Gene (Amst.) 195, 11-18[CrossRef][Medline] [Order article via Infotrieve]
  45. Kraner, S. D., Chong, J. A., Tsay, H. J., and Mandel, G. (1992) Neuron 9, 37-44[Medline] [Order article via Infotrieve]
  46. Mori, N., Schoenherr, C., Vandenbergh, D. J., and Anderson, D. J. (1992) Neuron 9, 45-54[Medline] [Order article via Infotrieve]
  47. Schoenherr, C. J., Paquette, A. J., and Anderson, D. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9881-9886[Abstract/Free Full Text]
  48. Morin, X., Cremer, H., Hirsch, M. R., Kapur, R. P., Goridis, C., and Brunet, J. F. (1997) Neuron 18, 411-423[CrossRef][Medline] [Order article via Infotrieve]
  49. Porzgen, P., Bonisch, H., Hammermann, R., and Bruss, M. (1998) Biochim. Biophys. Acta 1398, 365-370[Medline] [Order article via Infotrieve]
  50. Ramamoorthy, S., Prasad, P. D., Kulanthaivel, P., Leibach, F. H., Blakely, R. D., and Ganapathy, V. (1993) Biochemistry 32, 1346-1353[Medline] [Order article via Infotrieve]
  51. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428[Abstract]
  52. Ciccarone, V., Spengler, B. A., Meyers, M. B., Biedler, J. L., and Ross, R. A. (1989) Cancer Res. 49, 219-225[Abstract]
  53. Mercer, E. H., Hoyle, G. W., Kapur, R. P., Brinster, R. L., and Palmiter, R. D. (1991) Neuron 7, 703-716[Medline] [Order article via Infotrieve]
  54. Kobayashi, K., Morita, S., Mizuguchi, T., Sawada, H., Yamada, K., Nagatsu, I., Fujuta, K., and Nagatsu, T. (1994) J. Biol. Chem. 269, 29725-29731[Abstract/Free Full Text]
  55. Kobayashi, K., Sasaoka, T., Morita, S., Nagatsu, I., Iguchi, A., Kurosawa, Y., Fujita, K., Nomura, T., Kimura, M., Katsuki, M., and Nagatsu, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1631-1635[Abstract]
  56. Morita, S., Kobayashi, K., Mizuguchi, T., Yamada, K., Nagatsu, I., Titani, K., Fujita, K., Hidaka, H., and Nagatsu, T. (1993) Mol. Brain Res. 17, 239-244[Medline] [Order article via Infotrieve]
  57. Shaskus, J., Greco, D., Asnani, L. P., and Lewis, E. J. (1992) J. Biol. Chem. 267, 18821-18830[Abstract/Free Full Text]
  58. Hormuzdi, S. G., Penttinen, R., Jaenisch, R., and Bornstein, P. (1998) Mol. Cell. Biol. 18, 3368-3375[Abstract/Free Full Text]
  59. Smith, A. F., Bigsby, R. M., Word, R. A., and Herring, B. P. (1998) Am. J. Physiol. 274, C1188-C1195[Abstract/Free Full Text]
  60. Valarche, I., Jean-Philippe, T.-S., Marie-Rose, H., Salvador, M., Christo, G., and Brunet, J. F. (1993) Development 119, 881-896[Abstract/Free Full Text]
  61. Tiveron, M. C., Hirsch, M. R., and Brunet, J. F. (1996) J. Neurosci. 16, 7649-7660[Abstract/Free Full Text]
  62. Reis, D. J., Joh, T. H., Ross, R. A., and Pickel, V. M. (1974) Brain Res. 81, 380-386[Medline] [Order article via Infotrieve]
  63. Reis, D. J., Joh, T. H., and Ross, R. A. (1975) J. Pharmacol. Exp. Ther. 193, 775-784[Abstract]
  64. McMahon, A., Geertman, R., and Sabban, E. L. (1990) J. Neurosci. Res. 25, 395-404[Medline] [Order article via Infotrieve]
  65. Cubells, J. F., Baker, H., Volpe, B. T., Smith, G. P., Das, S. S., and Joh, T. H. (1995) Neurosci. Lett. 193, 189-192[CrossRef][Medline] [Order article via Infotrieve]
  66. Kim, K. T., Park, D. H., and Joh, T. H. (1993) J. Neurochem. 60, 946-951[Medline] [Order article via Infotrieve]
  67. Faisst, S., and Meyer, S. (1992) Nucleic Acids Res. 20, 3-26[Medline] [Order article via Infotrieve]
  68. Goodman, R. H. (1990) Annu. Rev. Neurosci. 13, 111-127[CrossRef][Medline] [Order article via Infotrieve]
  69. Jones, K. A., and Tjian, R. (1985) Nature 317, 179-182[Medline] [Order article via Infotrieve]
  70. Rajavashisth, T. B., Taylor, A. K., Andalibi, A., Svenson, K. L., and Lusis, A. J. (1989) Science 245, 640-643[Medline] [Order article via Infotrieve]
  71. Roesler, W. J., Vandenbark, G. R., and Hanson, R. W. (1988) J. Biol. Chem. 263, 9063-9066[Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.